Outlook Therapeutics, Inc.
Buffer formulations for enhanced antibody stability

Last updated:

Abstract:

The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.

Status:
Grant
Type:

Utility

Filling date:

16 Oct 2014

Issue date:

13 Aug 2019